Content overview: “Moderna and Merck's mRNA Cancer Vaccine Data Takes Center Stage at ESMO 2023”. At the European Society for Medical Oncology (ESMO) conference in Madrid, Moderna and Merck presented eagerly awaited results from their Phase 2b KEYNOTE-942 trial, showing that their personalized mRNA cancer vaccine mRNA-4157 (V940) combined with Merck's Keytruda reduced the risk of recurrence or death by 44% in patients with high-risk melanoma compared to Keytruda alone. The data, presented during a presidential session, also indicated a 65% reduction in the risk of distant metastasis or death, marking a potential turning point for individualized cancer immunotherapy.
The companies announced plans to initiate a Phase 3 trial in melanoma and expand into other tumor types, including non-small cell lung cancer. These results matter because they represent one of the first randomized demonstrations that a personalized mRNA cancer vaccine can improve outcomes, validating a technology that gained global attention during the COVID-19 pandemic. For the complete material, the listing points back to the source inside the network.